Oxygen Biotherapeutics, Inc., a development stage company, engages in developing biotechnology products that deliver oxygen to target tissues in the body in the US. The company primarily offers Oxycyte, a perfluorcarbon (PFC) based oil in water emulsion that carries oxygen and is been formulated for intravenous delivery for the treatment of traumatic brain injury, spinal cord injury, and decompression sickness; and other PFC-based oxygen carriers. It also provides Dermacyte line of topical cosmetic products that promote the appearance of skin health and other cosmetic benefits; and Wundecyte, a wound-healing gel. The Company licensed patent applications that relate to methods for non-pulmonary delivery of oxygen to tissue from Virginia Commonwealth University. The company has out-licensed an implantable glucose sensor.